Details
Stereochemistry | RACEMIC |
Molecular Formula | C23H25N5O5 |
Molecular Weight | 451.476 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COc1cc2c(cc1OC)nc([nH]c2=N)N3CCN(CC3)C(=O)C4COc5ccccc5O4
InChI
InChIKey=RUZYUOTYCVRMRZ-UHFFFAOYSA-N
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors. Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Originator
Sources: http://adisinsight.springer.com/drugs/800010345
Curator's Comment:: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
9.27 null [pKi] | |||
9.09 null [pKi] | |||
9.09 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARDURA Approved UseINDICATIONS AND USAGE
A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH:
obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete
emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency,
burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA
monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in
66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for
up to 14 weeks in double-blind studies and up to 2 years in open-label studies.
B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium
channel blockers, or angiotensin-converting enzyme inhibitors. Launch Date6.5750401E11 |
|||
Primary | CARDURA Approved UseINDICATIONS AND USAGE
A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the
urinary outflow obstruction and obstructive and irritative symptoms associated with BPH:
obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete
emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency,
burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In
patients with hypertension and BPH, both conditions were effectively treated with CARDURA
monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in
66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for
up to 14 weeks in double-blind studies and up to 2 years in open-label studies.
B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium
channel blockers, or angiotensin-converting enzyme inhibitors. Launch Date6.5750401E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
151.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
16 mg 1 times / day steady-state, oral dose: 16 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
42.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
65.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
162 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
268 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2139337/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
16 mg 1 times / day steady-state, oral dose: 16 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2951261/ |
8 mg 1 times / day steady-state, oral dose: 8 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DOXAZOSIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
60 mg single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
Disc. AE: Sinus tachycardia... AEs leading to discontinuation/dose reduction: Sinus tachycardia (1 patient) Sources: |
16 mg single, oral (max) Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: |
unhealthy, adult n = 665 Health Status: unhealthy Condition: Hypertension Age Group: adult Sex: unknown Population Size: 665 Sources: |
DLT: Postural edema... Dose limiting toxicities: Postural edema (2.7%) Sources: |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
healthy, adult n = 35 Health Status: healthy Age Group: adult Sex: unknown Population Size: 35 Sources: |
Disc. AE: Orthostatic dizziness... AEs leading to discontinuation/dose reduction: Orthostatic dizziness (1 patient) Sources: |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Disc. AE: Fatigue, Urinary incontinence... Other AEs: Rhinitis... AEs leading to discontinuation/dose reduction: Fatigue (3 patients) Other AEs:Urinary incontinence (2 patients) Rhinitis (1 patient) Sources: |
8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Other AEs: Nausea, Constipation... Other AEs: Nausea (below serious, 2 patients) Sources: Constipation (below serious, 1 patient) Allergy (below serious, 1 patient) Dizziness (below serious, 1 patient) Numbness (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sinus tachycardia | 1 patient Disc. AE |
60 mg single, oral Overdose |
healthy, 19 years n = 1 Health Status: healthy Age Group: 19 years Sex: F Population Size: 1 Sources: |
Postural edema | 2.7% DLT |
16 mg single, oral (max) Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: |
unhealthy, adult n = 665 Health Status: unhealthy Condition: Hypertension Age Group: adult Sex: unknown Population Size: 665 Sources: |
Orthostatic dizziness | 1 patient Disc. AE |
4 mg 1 times / day steady, oral Recommended Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: |
healthy, adult n = 35 Health Status: healthy Age Group: adult Sex: unknown Population Size: 35 Sources: |
Rhinitis | 1 patient | 16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Urinary incontinence | 2 patients Disc. AE |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Fatigue | 3 patients Disc. AE |
16 mg 1 times / day steady, oral (max) Highest studied dose Dose: 16 mg, 1 times / day Route: oral Route: steady Dose: 16 mg, 1 times / day Sources: |
unhealthy, mean 59 years n = 97 Health Status: unhealthy Condition: Hypertension Age Group: mean 59 years Sex: M+F Population Size: 97 Sources: |
Allergy | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Constipation | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Dizziness | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Numbness | below serious, 1 patient | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Nausea | below serious, 2 patients | 8 mg 1 times / day steady, oral Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: |
unhealthy n = 22 Health Status: unhealthy Condition: cocaine dependence Population Size: 22 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: Boceprevir may increase doxazosin concentrations through CYP3A inhibition |
|||
minor | ||||
minor | ||||
minor |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. | 2001 |
|
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. | 2001 |
|
Is postural hypotension a real problem with antihypertensive medication? | 2001 |
|
Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: the role of general practice databases. | 2001 |
|
Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. | 2001 |
|
Reduced heat shock proteins: a mechanism to explain higher cardiovascular events associated with doxazosin. | 2001 Apr |
|
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). | 2001 Apr |
|
Recent clinical trial highlights in hypertension. | 2001 Apr |
|
Lessons learned from prematurely terminated clinical trials. | 2001 Aug |
|
Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-beta1. | 2001 Aug 1 |
|
Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes. | 2001 Dec |
|
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension. | 2001 Dec 18 |
|
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). | 2001 Feb |
|
Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects. | 2001 Jan |
|
[Bilateral pheochromocytoma: laparoscopic surgery in 2 cases]. | 2001 Jan |
|
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors. | 2001 Jan |
|
Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure. | 2001 Jul |
|
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. | 2001 Jul |
|
Role of alpha1-blockade in congenital long QT syndrome: investigation by exercise stress test. | 2001 Jul |
|
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. | 2001 Jul 1 |
|
Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy. | 2001 Jul-Aug |
|
[Long-term therapy of benign prostatic hyperplasia. Our experience]. | 2001 Mar |
|
The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. | 2001 Mar |
|
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. | 2001 May |
|
Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension. | 2001 May |
|
Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes. | 2001 May |
|
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice]. | 2001 May 31 |
|
Effects of antihypertensive agents on blood pressure during exercise. | 2001 Nov |
|
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. | 2001 Nov |
|
Doxazosin and congestive heart failure. | 2001 Nov 1 |
|
A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. | 2001 Oct |
|
Heart lines. Cardura update. | 2001 Sep |
|
Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. | 2002 |
|
Influence of the alpha-1-adrenergic receptor blocker doxazosin on exercise-induced hyperkalemia in hemodialysis patients. | 2002 |
|
Acute effects of serotonin on rat bladder contractility. | 2002 |
|
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. | 2002 Aug |
|
Two-drug therapy is best for symptomatic prostate enlargement: combination should change clinical practice. | 2002 Aug |
|
Medical therapy for benign prostatic hyperplasia progression. | 2002 Aug |
|
Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro. | 2002 Aug-Sep |
|
The use of alpha-adrenoceptor antagonists in lower urinary tract disease. | 2002 Feb |
|
Stability-indicating methods for the determination of doxazosin mezylate and celecoxib. | 2002 Feb 1 |
|
Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. | 2002 Jan |
|
Stroke associated with alpha blocker therapy for benign prostatic hypertrophy. | 2002 Jan |
|
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. | 2002 Jan 15 |
|
Psychological characteristics and responses to antihypertensive drug therapy. | 2002 Jan-Feb |
|
Treatment of hypertension in the elderly. | 2002 Jan-Feb |
|
alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. | 2002 Jul |
|
Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. | 2002 Jul 22 |
|
Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. | 2002 May-Jun |
|
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. | 2002 Sep 3 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/doxazosin.html
Usual Adult Dose for Hypertension
Initial dose: 1 mg orally once a day.
Maintenance dose: 1 to 16 mg orally once a day.
Usual Adult Dose for Benign Prostatic Hyperplasia
Initial dose:
Immediate-release: 1 mg orally once a day.
Extended-release: 4 mg orally once a day with breakfast
Maintenance dose:
Immediate-release: 1 to 8 mg orally once a day.
Extended-release: 4 to 8 mg orally once a day with breakfast. Depending on the patient's symptomatic response and tolerability, the dose may be increased to 8 mg (the maximum recommended dose). The recommended titration interval is 3 to 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2977161
Ring segments of splanchnic, peripheral, coronary, pulmonary and uterine conduit arteries obtained during surgery were studied in tissue baths. Resistance arteries dissected from various sites were studied in a myograph. Both conduit and resistance vessels contracted in response to the alpha 1-agonist phenylephrine (10(-7) to 10(-4) mol/l), an effect that was antagonized by the alpha 1-antagonist doxazosin (10(-8) to 10(-6) mol/l).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175553
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
||
|
NDF-RT |
N0000000099
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
||
|
LIVERTOX |
325
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
||
|
WHO-VATC |
QC02CA04
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
||
|
WHO-ATC |
C02CA04
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DOXAZOSIN
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
49276
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | RxNorm | ||
|
74191-85-8
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
3157
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
Doxazosin
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
5143
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
M4752
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL707
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
7170
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
954
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
C61737
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
74191-85-8
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
D017292
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
NW1291F1W8
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
137888-77-8
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
SUPERSEDED | |||
|
SUB06384MIG
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY | |||
|
DB00590
Created by
admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)